• Publications
  • Influence
Inflammatory monocytes regulate pathologic responses to commensals during acute gastrointestinal infection
The commensal flora can promote both immunity to pathogens and mucosal inflammation. How commensal-driven inflammation is regulated in the context of infection remains poorly understood. Here, weExpand
  • 186
  • 10
AllergoOncology: the role of IgE‐mediated allergy in cancer
Epidemiological studies have suggested inverse associations between allergic diseases and malignancies. As a proof of concept for the capability of immunoglobulin E (IgE) to destruct tumor cells,Expand
  • 169
  • 4
The Lymphoid Variant of Hypereosinophilic Syndrome
AbstractThe CD3-CD4+ aberrant T-cell phenotype is the most described in the lymphoid variant of hypereosinophilic syndrome (L-HES), a rare form of HES. Only a few cases have been reported, and dataExpand
  • 51
  • 3
Human Eosinophils Exert TNF-α and Granzyme A-Mediated Tumoricidal Activity toward Colon Carcinoma Cells
Peripheral blood and tissue eosinophilia is a prominent feature in allergic diseases and helminth infections. In cancer patients, tumor-associated tissue eosinophilia is frequently observed.Expand
  • 96
  • 3
TLR2-dependent eosinophil interactions with mycobacteria: role of alpha-defensins.
Peripheral blood and tissue eosinophilia are a prominent feature in allergic diseases and during helminth infections. Eosinophil recruitment also frequently occurs upon mycobacterial infections,Expand
  • 78
  • 2
Eosinophil-derived IFN-gamma induces airway hyperresponsiveness and lung inflammation in the absence of lymphocytes.
BACKGROUND Eosinophils are key players in T(H)2-driven pathologies, such as allergic lung inflammation. After IL-5- and eotaxin-mediated tissue recruitment, they release several cytotoxic andExpand
  • 49
  • 2
The eosinophil surface receptor epidermal growth factor-like module containing mucin-like hormone receptor 1 (EMR1): a novel therapeutic target for eosinophilic disorders.
BACKGROUND Although several novel agents are currently in clinical trials for eosinophilic disorders, none has demonstrated efficacy in reducing blood and tissue eosinophilia in all subjects.Expand
  • 43
  • 1
  • PDF
The Spectrum of FIP1L1-PDGFRA-Associated Chronic Eosinophilic Leukemia
AbstractImatinib is the treatment of choice for FIP1L1/PDGFRA (F/P)-associated chronic eosinophilic leukemia (F/P+ CEL), but its optimal dosing, duration, and possibility of discontinuation are stillExpand
  • 61
  • 1
Benralizumab for PDGFRA‐Negative Hypereosinophilic Syndrome
Background Hypereosinophilic syndrome is a group of diseases defined by marked eosinophilia in blood or tissue and eosinophil‐related clinical manifestations. Benralizumab is a monoclonal antibodyExpand
  • 30
  • 1
CR3-dependent negative regulation of human eosinophils by Mycobacterium bovis BCG lipoarabinomannan.
Eosinophils have recently been shown to participate in innate immune responses against mycobacteria. We have investigated whether Mycobacterium bovis BCG regulate the human eosinophil immuneExpand
  • 4
  • 1